We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gastric Banding Has Poor Long-Term Outcomes

By HospiMedica International staff writers
Posted on 06 Apr 2011
Laparoscopic adjustable gastric banding (LAGB), an obesity treatment gaining wider acceptance, appears to produce relatively poor long-term outcomes, according to a new study.

Researchers at Saint Pierre University Hospital (Brussels, Belgium) conducted a clinical assessment of 151 consecutive patients (median age 50 years) who had benefited from LAGB between January 1, 1994, and December 31, 1997, to determine the long-term efficacy and safety of LAGB for morbid obesity 12 years after the procedure. More...
The main outcome measures were mortality rate, number of major and minor complications, number of corrective operations, number of patients who experienced weight loss, evolution of co-morbidities, patient satisfaction, and quality of life.

The results showed that the overall rate of follow-up was 54.3%. The long-term mortality rate from unrelated causes was 3.7%, but operative mortality rate was zero. In all, 22% of the patients experienced minor complications, and 39% experienced major complications, including 28% who experienced band erosion; 17% of the patients had their procedure switched to laparoscopic Roux-en-Y gastric bypass. Overall, the mean excess weight loss was 42.8%; 36 patients (51.4%) still had their band, and their mean excess weight loss was 48%. The quality-of-life score was neutral, and satisfaction index was good for 60.3% of patients. The study was published in the March 21, 2011, issue of the Archives of Surgery.

"Nearly 1 out of 3 patients experienced band erosion, and nearly 50% of the patients required removal of their bands, contributing to a reoperation rate of 60%,” concluded lead author Jacque Himpens, MD, and colleagues of the department of gastrointestinal surgery. "The high failure rate of LAGB, at least in our hands, could be detrimental to its future continued widespread use as a restrictive weight loss operation.”

The researchers clarified that as the procedures were performed in the 1990s, they had used the older perigastric dissection technique. Some current evidence, however, suggests that the more recent pars flaccida technique, combined with wider, softer bands, may provide better overall results.

Related Links:

Saint Pierre University Hospital





Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.